Objectives: Antimicrobial drug resistance is a growing problem in Europe and, even with differences in epidemiology, it is of great concern. The treatment of complicated skin and soft-tissue infections (cSSTIs) and complicated intra-abdominal infections (cIAIs) is hindered further by pathogens that are resistant to methicillin, carbapenems, third-generation cephalosporins and glycopeptides.
Patients And Methods: An analysis of the microbiological results from five European observational studies (July 2006 to October 2011) evaluating the efficacy of tigecycline (prescribed as monotherapy or in combination with other antibacterials) for the treatment of cSSTI and cIAI is presented.
Results: In total, 213 cSSTI and 623 cIAI patients were included; 34.4% and 56.6%, respectively, were critically ill in intensive care units. At baseline, at least one pathogen was isolated in 167 (78.4%) cSSTI and 464 (74.5%) cIAI patients, and 32.9% and 49.1% of infections were polymicrobial. In cSSTI, Staphylococcus aureus and Escherichia coli (52.7% and 18.0%, respectively) were the most frequently isolated pathogens, whereas in cIAI most infections were due to E. coli (41.8%), Enterococcus faecium (40.1%) and Enterococcus faecalis (21.1%). Clinical response was observed in >80% of patients with E. coli in both cIAI and cSSTI. In cSSTI patients, the clinical response rate to S. aureus was 80.8%. For cIAI, 77.4% of E. faecium and 79.5% of E. faecalis patients responded to treatment.
Conclusions: Tigecycline when given alone or in combination with other antibacterials appeared to be efficacious against multiple pathogens, affirming its role in real-life clinical practice as a broad-spectrum antibacterial for the treatment of patients with cSSTI and cIAI, including the critically ill, across Europe.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jac/dkt144 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Curcumin reverses high-level tigecycline resistance mediated by different mechanisms in Gram-negative bacteria.
Phytomedicine
December 2024
College of Veterinary Medicine, Henan Agricultural University, Zhengzhou, PR China; Ministry of Education Key Laboratory for Animal Pathogens and Biosafety, Zhengzhou, Henan Province, PR China; Henan Province Key Laboratory of Animal Food Pathogens SurveillancePR China. Electronic address:
Background: Tigecycline is one of the few effective treatments for multidrug-resistant bacteria. However, the recent emergence and spread of high-level tigecycline resistance in Enterobacteriaceae have significantly limited its clinical use. To combat this challenge, combining antibiotics with adjuvants has emerged as a promising strategy.
View Article and Find Full Text PDFEffect of colistin-tigecycline combination on colistin-resistant and carbapenem-resistant and .
Microbiol Spectr
December 2024
Department of Microbiology, Sungkyunkwan University School of Medicine, Suwon, South Korea.
Unlabelled: There is a critical need for treatment strategies to combat carbapenem-resistant Gram-negative pathogens. This study investigates the efficacy of combining low concentrations of colistin with tigecycline against colistin- and carbapenem-resistant and strains. We used two strains of KPC-2-producing and OXA-23-producing , both of which are highly colistin-resistant.
View Article and Find Full Text PDFResilience of tigecycline heteroresistance phenotype in Acinetobacter baumannii.
J Antimicrob Chemother
December 2024
Department of Microbiology, School of Medicine, Sungkyunkwan University, Suwon, Republic of Korea.
Background: Heteroresistance, frequently observed in diverse bacterial species, imposes clinical challenges. For this study, we investigated the stability and resilience of tigecycline heteroresistance in Acinetobacter baumannii.
Methods: Four tigecycline-heteroresistant (HR) A.
Efficacy and safety of eravacycline versus tigecycline for complicated intra-abdominal infections in the ICU: a multicenter, single-blind, parallel randomized controlled trial study protocol.
Front Med (Lausanne)
November 2024
Intensive Care Unit, Ansteel Group General Hospital, Anshan, China.
Background: Complicated intra-abdominal infections (cIAIs), often caused by multidrug-resistant bacteria such as carbapenem-resistant (CRAB) and carbapenem-resistant Enterobacteriaceae (CRE) are a critical challenge in ICUs. Owing to their high mortality and treatment failure rates, there is an urgent need for effective therapies. This trial will compare eravacycline to tigecycline for treating cIAIs in patients in the ICU, aiming to provide a superior treatment option.
View Article and Find Full Text PDFEfficacy of colistin-based combinations against pandrug-resistant whole-genome-sequenced Klebsiella pneumoniae isolated from hospitalized patients in Egypt: an in vitro/vivo comparative study.
Gut Pathog
December 2024
Microbiology and Immunology Department, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
Background: Colistin resistance significantly constrains available treatment options and results in the emergence of pandrug-resistant (PDR) strains. Treating PDR infections is a major public health issue. A promising solution lies in using colistin-based combinations.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!